NICE support Bayer’s and Novartis treatments for sight condition
NICE have issued updated guidelines for the treatment of wet age-related macular degeneration, by continuing to back use of both Bayer’s Eylea and Novartis’ Lucentis.
According to the guidelines issued by NICE, the intravitreal anti-vascular endothelial growth factor (VEGF) treatment should be recommended for late AMD (wet active) for eyes with visual acuity within a specified range.
Lucentis or Eylea can be considered a treatment option if:
- the best-corrected visual acuity is between 6/12 and 6/96;
- there is no permanent structural damage to the central fovea;
- the lesion size is less than or equal to 12-disc areas in greatest linear dimension;
- there is evidence of recent presumed disease progression
It was also noted that in both cases NICE’s endorsement is contingent on the continued provision of a patient access scheme, which reduced the cost of these drugs to the NHS.
AMD is the most common cause of vision loss in adults, with approximately 39,700 new cases identified in the UK every year. Neovascular or Wet AMD can be treated if caught early, which Bayer notes reinforces the importance of prompt referral to a hospital specialist.
As a result, the clinical guideline recommends that urgent referrals to macular services for people with suspected wet AMD are made within one working day and, for those with confirmation of the disease and are also eligible for treatment with anti-VEGF therapies, treatment should be offered as soon as possible and within 14 days.
“Bayer strongly believes that all patients with wet AMD should receive timely access to sight-preserving treatment with a licensed medicine within the NHS,” said Dr Jackie Napier, medical director, Ophthalmology, at Bayer.
“We are encouraged by the provision of this guideline giving the clinical community the reassurance of having access to rigorously tested products to effectively treat this ageing and vulnerable population.”
However, guidelines for the treatment of wet-AMD in the UK remain contentious, as some believe there is another option for managing the condition off-label that is much cheaper.
Roche/Genetech’s Avastin (bevacizumab), which is also an anti-VEGF therapy, is not licensed to treatment wet-AMD despite trials have shown that it is as safe and effective (IVAN trial), and much cheaper.
NHS Clinical Commissioners also supports the drug’s use in this setting.
“Where cheaper medicines that are equally clinically effective as a more expensive alternative are available, we call on the Department of Health to ensure that every possible avenue is explored to enable these savings to be realised. The time to take action on the use of this drug at a national level, to release cost-savings to use in other priority areas, is now,” it said in a statement, as reported by the paper.
The European Court has in effect ruled out blanket policies that allow off-label prescribing of medicines on the grounds of cost, which is also reflected in MHRA guidelines which stress that cost, convenience or operational needs cannot be factors driving the decision to do so.
However, in response to NICE’s new guidelines, the General Medical Council has issued a statement to reassure doctors that where they are “working in partnership with patients, following clinical guidance and making prescribing decisions in good faith on the basis of evidence and experience, the use of Avastin would not cause us any concerns”.
“In an ideal world a licensing solution for using Avastin would be found as the rigours of the licensing regime provide important assurances of patient safety. However, in the absence of this and given the clinical support for using Avastin, including from the Royal College of Ophthalmologists, we want to reassure doctors that this prescribing decision alone would not raise fitness to practice concerns, providing doctors are applying the broader principles of our guidance,” said GMC chief executive Charlie Massey.